SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a new asset-light business model designed to scale AI cloud capacity via infrastructure partners, while simultaneously navigating sector-wide volatility linked to data center development concerns. The community is actively debating the company's long-term valuation and fundamental strength, with many investors using the recent price pullback as an opportunity to build positions ahead of future earnings.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently experiencing intense volatility as its stock price tests long-term technical support, driven by a broader sector-wide selloff and investor frustration with recent market performance. While many retail traders are debating whether to buy the dip or cut losses, sentiment is divided between those bracing for further downside and long-term believers betting that continued business execution and upcoming engine test milestones will provide a catalyst for recovery.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant market pressure as investors react to a $1 billion convertible note offering, raising concerns about dilution and management's previous capital commitments. While many community members are venting frustration over the timing of this financing, others are highlighting the deal's favorable terms and long-term potential for accelerating satellite deployment and securing launch independence.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors weigh significant regulatory progress against ongoing frustration over missed operational targets, leading to high-volume debates between those anticipating a major short squeeze and those skeptical of the company's long-term commercialization timeline. The community remains deeply divided, focusing heavily on upcoming criticality milestones for the Groves reactor and the impact of continued insider share sales on the stock's performance.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and intense investor interest following reports that Eli Lilly is in advanced talks to acquire the company at a significant premium. While shareholders are actively debating the merits of the deal versus the company's long-term pipeline potential, the market is pricing in the acquisition with considerable speculation over whether a bidding war will emerge.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing significant volatility as investors rotate away from semiconductor stocks, fueled by broader market concerns and frustration over the stock's recent performance following high-profile industry hype. Community discourse is currently split between those panicking over the sharp correction and others aggressively scaling into positions, betting that the long-term AI infrastructure thesis remains intact despite the technical breakdown.

Oracle Corporation. The Group's principal activities are to develop, manufacture, market, distribute and service computer software. It has two businesses, software and services, which are further divided into five segments. Its software business consist of two segments: The new software license segment is engaged in the licensing of database, middleware software and applications software.The software license updates and product support segment provides customers with rights to unspecified software product upgrades and maintenance releases, internet access to technical content, internet and telephone access to technical support personnel. Its services business is comprised of three segments: The consulting segment provides services in business strategy and analysis, business process simplification, solutions integration and the implementation, enhancement and upgrade of database, middleware and applications software. On Demand includes Oracle On Demand and Advanced Customer Services.

Oracle Corp.

Oracle is experiencing significant volatility as investors debate whether recent price declines represent a bottoming process or continued downside due to concerns over heavy AI-related debt and capital expenditure. The stock is currently seeing a tug-of-war between retail traders looking for a recovery based on major cloud contract rumors and institutional bears skeptical of the company's long-term reliance on AI infrastructure spending.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased investor optimism following a robust earnings report that beat consensus estimates and featured a raised full-year profit outlook. The community is actively discussing the stock's strong margin control and recovery, with many traders viewing the recent price action as a pivot toward long-term value despite ongoing sector-wide scrutiny.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMC is trending as its record-breaking revenue and massive June growth surge confirm that the demand for AI infrastructure and advanced semiconductors remains extremely strong. While the broader chip sector has faced recent volatility, the community is actively debating whether the stock's muted price reaction to these blowout fundamentals signals a healthy consolidation or an over-stretched valuation.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing extreme volatility and heavy retail attention following a sharp price swing triggered by reports of bankruptcy rumors, which the company categorically denied through an SEC filing and a cease-and-desist. The community is deeply divided, with bulls actively coordinating to trigger a short squeeze against a high borrow fee backdrop, while bears remain focused on long-term concerns regarding cash burn and liquidity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody PR Newswire SAN...

Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz

The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii...

Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.

Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average   - What's Next?

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 50-Day Moving Average - Here's What Happened...

Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving Average - Time to Sell?

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above Fifty Day Moving Average - Should You Sell...

Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Wall Street Zen raised shares of Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Sunday...

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Spero Therapeutics Inc

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled

Equity

Bearish Sentiment

Memory - $MU, $SNDK, $STX, $SKHY, etc.

Neoclouds - $NBIS, $CRWV, $IREN, $APLD, etc.

Space - $RKLB, $SPCX, $ASTS, $VOYG, etc.

Neoclouds, space, and memory are among the market's most beaten-down sectors over the past week - all trading well off their recent highs despite strong underlying demand. Which are you most interested in buying right now? Explain your reasoning in the comments.

Which beaten-down industry are you most interested in adding exposure to?

Current Price	$1.59
Prev Close	$1.70
Open	$1.68
Dividend Yield	0.00%
50-Day Moving Average	$2.48
Beta	0.94
Avg. Volume	1.76M
PE Ratio	6.98

52-Week High	$3.08
52-Week Low	$1.63
Market Capitalization	$98.43M
EPS (Annual)	$0.1452
Price to Book	1.86
Revenue Per Employee	$2.38M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SPROSpero Therapeutics Inc

Latest SPRO News